|
1
|
Covic A, Mircescu G, Gluhovschi G and
Schiller A: Ghiduri de practica medicala. Boala cronica de rinichi.
1-109. 2007. Bucuresti AG de practica medicala. SR de N: No
Title.
|
|
2
|
Evans RW, Manninen DL, Garrison LP Jr,
Hart LG, Blagg CR, Gutman RA, Hull AR and Lowrie EG: The quality of
life of patients with end-stage renal disease. N Engl J Med.
312:553–559. 1985.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Laupacis A, Keown P, Pus N, Krueger H,
Ferguson B, Wong C and Muirhead N: A study of the quality of life
and cost-utility of renal transplantation. Kidney Int. 50:235–242.
1996.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Simmons RG and Abress L: Quality-of-life
issues for end-stage renal disease patients. Am J Kidney Dis.
15:201–208. 1990.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ojo AO, Hanson JA, Wolfe RA, Leichtman AB,
Agodoa LY and Port FK: Long-term survival in renal transplant
recipients with graft function. Kidney Int. 57:307–313.
2000.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Organ procurement and transplantation
network and scientific registry of transplant recipients 2010 data
report. Am J Transplant. 12 (Suppl 1):S1–S156. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Foroutan F, Friesen EL, Clark KE, Motaghi
S, Zyla R, Lee Y, Kamran R, Ali E, De Snoo M, Orchanian-Cheff A, et
al: Risk factors for 1-year graft loss after kidney transplantation
systematic review and meta-analysis. Clin J Am Soc Nephrol.
14:1642–1650. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wyburn KR, Jose MD, Wu H, Atkins RC and
Chadban SJ: The role of macrophages in allograft rejection.
Transplantation. 80:1641–1647. 2005.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Williams TM: Human leukocyte antigen gene
polymorphism and the histocompatibility laboratory. J Mol
Diagnostics. 3:98–104. 2001.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Horton R, Wilming L, Rand V, Lovering RC,
Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot CC Jr, Wright MW,
et al: Gene map of the extended human MHC. Nat Rev Genet.
5:889–899. 2004.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Sayegh MH and Turka LA: The role of T-cell
costimulatory activation pathways in transplant rejection. N Engl J
Med. 338:1813–1821. 1998.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Osińska I, Popko K and Demkow U: Perforin:
An important player in immune response. Cent Eur J Immunol.
39:109–115. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Vella J: Transplantation immunobiology.
UpToDate, 2021.
|
|
14
|
Mukherjee S and Mukherjee U: A
comprehensive review of immunosuppression used for liver
transplantation. J Transplant. 2009(701464)2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bull MR, Spicer JA, Huttunen KM, Denny WA,
Ciccone A, Browne KA, Trapani JA and Helsby NA: The preclinical
pharmacokinetic disposition of a series of perforin-inhibitors as
potential immunosuppressive agents. Eur J Drug Metab Pharmacokinet.
40:417–425. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lu P, Garcia-Sanz JA, Lichtenheld MG and
Podack ER: Perforin expression in human peripheral blood
mononuclear cells: Definition of an IL-2-independent pathway of
perforin induction in CD8+ T cells. J Immunol. 148:3354–3360.
1992.PubMed/NCBI
|
|
17
|
Pipkin ME, Ljutic B, Cruz-Guilloty F,
Nouzova M, Rao A, Zúñiga-Pflücker JC and Lichtenheld MG: Chromosome
transfer activates and delineates a locus control region for
perforin. Immunity. 26:29–41. 2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Keefe D, Shi L, Feske S, Massol R, Navarro
F, Kirchhausen T and Lieberman J: Perforin triggers a plasma
membrane-repair response that facilitates CTL induction of
apoptosis. Immunity. 23:249–262. 2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kägi D, Ledermann B, Bürki K, Zinkernagel
RM and Hengartner H: Molecular mechanisms of lymphocyte-mediated
cytotoxicity and their role in immunological protection and
pathogenesis in vivo. Annu Rev Immunol. 14:207–232. 1996.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Henkart PA: Mechanism of
lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 3:31–58.
1985.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fujinaka H, Yamamoto T, Feng L, Nameta M,
Garcia G, Chen S, El-shemi AA, Ohshiro K, Katsuyama K, Yoshida Y,
et al: Anti-perforin antibody treatment ameliorates experimental
crescentic glomerulonephritis in WKY rats. Kidney Int. 72:823–830.
2007.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cecka JM, Cho YW and Terasaki PI: Analyses
of the UNOS scientific renal transplant registry at three
years-early events affecting transplant success. Transplantation.
53:59–63. 1992.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mitchell RN and Libby P: Vascular
remodeling in transplant vasculopathy. Circ Res. 100:967–978.
2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Almond PS, Matas A, Gillingham K, Dunn DL,
Payne WD, Gores P, Gruessner R and Najarian JS: Risk factors for
chronic rejection in renal allograft recipients. Transplantation.
55:752–756; discussion 756-7. 1993.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Miltenburg AM, Meijer-Paape ME, Daha MR,
van Bockel JH, Weening JJ, van Es LA and van*der*Woude FJ:
Donor-specific lysis of human kidney proximal tubular epithelial
cells by renal allograft-infiltrating lymphocytes. Transplantation.
48:296–302. 1989.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wever PC, Boonstra JG, Laterveer JC, Hack
CE, van Der Woude FJ, Daha MR and ten*Berge IJ: Mechanisms of
lymphocyte-mediated cytotoxicity in acute renal allograft reaction.
Transplantation. 66:259–264. 1998.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cecka JM: The UNOS scientific renal
transplant registry-2000. Clin Transpl. 1-18:2000.PubMed/NCBI
|
|
28
|
Owen WF and Lowrie EG: C-reactive protein
as an outcome predictor for maintenance hemodialysis patients.
Kidney Int. 54:627–636. 1998.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Guessous I, Ponte B, Marques-Vidal P,
Paccaud F, Gaspoz JM, Burnier M, Waeber G, Vollenweider P and
Bochud M: Clinical and biological determinants of kidney outcomes
in a population-based cohort study. Kidney Blood Press Res.
39:74–85. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Csaba P, Kovesdy*Kopple JD and
Kalantar-Zadeh K: Inflammation in renal insufficiency. UpToDate,
2011.
|
|
31
|
López-Gómez JM, Pérez-Flores I, Jofré R,
Carretero D, Rodríguez-Benitez P, Villaverde M, Pérez-García R,
Nassar GM, Niembro E and Ayus JC: Presence of a failed kidney
transplant in patients who are on hemodialysis is associated with
chronic inflammatory state and erythropoietin resistance. J Am Soc
Nephrol. 15:2494–2501. 2004.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Mas VR, Mas LA, Archer KJ, Yanek K, King
AL, Gibney EM, Cotterell A, Fisher RA, Posner M and Maluf DG:
Evaluation of gene panel mrnas in urine samples of kidney
transplant recipients as a non-invasive tool of graft function. Mol
Med. 13:315–324. 2007.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Choy JC: Granzymes and perforin in solid
organ transplant rejection. Cell Death Differ. 17:567–576.
2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Hameed A, Truong LD, Price V, Kruhenbuhl O
and Tschopp J: Immunohistochemical localization of granzyme B
antigen in cytotoxic cells in human tissues. Am J Pathol.
138:1069–1075. 1991.PubMed/NCBI
|
|
35
|
Griffiths GM, Namikawa R, Mueller C, Liu
CC, Young JD, Billingham M and Weissman I: Granzyme A and perforin
as markers for rejection in cardiac transplantation. Eur J Immunol.
21:687–692. 1991.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ciément MV, Haddad P, Soulié A, Benvenuti
C, Lichtenheld MG, Podack ER, Sigaux N and Sasportes M: Perform and
granzyme B as markers for acute rejection in heart transplantation.
Int Immunol. 3:1175–1181. 1991.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lipman ML, Stevens AC and Strom TB:
Heightened intragraft CTL gene expression in acutely rejecting
renal allografts. J Immunol. 152:5120–5127. 1994.PubMed/NCBI
|
|
38
|
Kummer JA, Wever PC, Kamp AM, ten Berge
IJ, Hack CE and Weening JJ: Expression of granzyme A and B proteins
by cytotoxic lymphocytes involved in acute renal allograft
rejection. Kidney Int. 47:70–77. 1995.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Krams SM, Villanueva JC, Quinn MB and
Martinez OM: Expression of the cytotoxic T cell mediator granzyme B
during liver allograft rejection. Transpl Immunol. 3:162–166.
1995.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Legros-Maïda S, Soulié A, Benvenuti C,
Wargnier A, Vallée N, Berthou C, Guillet J, Sasportes M and Sigaux
N: Granzyme B and perforin can be used as predictive markers of
acute rejection in heart transplantation. Eur J Immunol.
24:229–233. 1994.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Yannaraki M, Rebibou JM, Ducloux D, Saas
P, Duperrier A, Felix S, Rifle G, Chalopin JM, Hervé P, Tiberghien
P and Ferrand C: Urinary cytotoxic molecular markers for a
noninvasive diagnosis in acute renal transplant rejection. Transpl
Int. 19:759–768. 2006.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Li B, Hartono C, Ding R, Sharma VK,
Ramaswamy R, Qian B, Serur D, Mouradian J, Schwartz JE and
Suthanthiran M: Noninvasive diagnosis of renal-allograft rejection
by measurement of messenger RNA for perforin and granzyme B in
urine. N Engl J Med. 344:947–954. 2001.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Graziotto R, Del Prete D, Rigotti P,
Anglani F, Baldan N, Furian L, Valente M, Antonello A, Marchini F,
D'Angelo A and Gambaro G: Perforin, Granzyme B, and Fas ligand for
molecular diagnosis of acute renal-allograft rejection: Analyses on
serial biopsies suggest methodological issues. Transplantation.
81:1125–1132. 2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Strehlau J, Pavlakis M, Lipman M, Shapiro
M, Vasconcellos L, Harmon W and Strom TB: Quantitative detection of
immune activation transcripts as a diagnostic tool in kidney
transplantation. Proc Natl Acad Sci USA. 94:695–700.
1997.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Campistol JM, Iñigo P, Larios S, Bescos M
and Oppenheimer F: Role of transforming growth factor-beta1 in the
progression of chronic allograft nephropathy. Nephrol Dial
Transplant. 16 (Suppl 1):S114–S116. 2001.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Nocera A, Tagliamacco A, De Palma R, Del
Galdo F, Ferrante A, Fontana I, Barocci S, Ginevri F, Rolla D,
Ravetti JL and Valente U: Cytokine mRNA expression in chronically
rejected human renal allografts. Clin Transplant. 18:564–570.
2004.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Pribylova-Hribova P, Kotsch K, Lodererova
A, Viklicky O, Vitko S, Volk HD and Lacha J: TGF-beta1 mRNA
upregulation influences chronic renal allograft dysfunction. Kidney
Int. 69:1872–1879. 2006.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Shin GT, Kim SJ, Lee TS, Oh CK and Kim H:
Gene expression of perforin by peripheral blood lymphocytes as a
marker of acute rejection. Nephron Clin Pract. 100:c63–c70.
2005.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Trapani JA and Smyth MJ: Functional
significance of the perforin/granzyme cell death pathway. Nat Rev
Immunol. 2:735–747. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
50
|
Pascoe MD, Marshall SE, Welsh KI, Fulton
LM and Hughes DA: Increased accuracy of renal allograft rejection
diagnosis using combined perforin, granzyme B, and Fas ligand
fine-needle aspiration immunocytology. Transplantation.
69:2547–2553. 2000.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Ajith A, Portik-Dobos V, Nguyen-Lefebvre
AT, Callaway C, Horuzsko DD, Kapoor R, Zayas C, Maenaka K, Mulloy
LL and Horuzsko A: HLA-G dimer targets Granzyme B pathway to
prolong human renal allograft survival. FASEB J. 33:5220–5236.
2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Tampio J, Huttunen J, Montaser A and
Huttunen KM: Targeting of perforin inhibitor into the brain
parenchyma via a prodrug approach can decrease oxidative stress and
neuroinflammation and improve cell survival. Mol Neurobiol.
57:4563–4577. 2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
D'Angelo ME, Dunstone MA, Whisstock JC,
Trapani JA and Bird PI: Perforin evolved from a gene duplication of
MPEG1, followed by a complex pattern of gene gain and loss within
Euteleostomi. BMC Evol Biol. 12(59)2012.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Araujo-Voces M and Quesada V: Frequent
birth-and-death events throughout perforin-1 evolution. BMC Evol
Biol. 20(135)2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
De Rosa SC, Andrus JP, Perfetto SP,
Mantovani JJ, Herzenberg LA, Herzenberg LA and Roederer M: Ontogeny
of gamma delta T cells in humans. J Immunol. 172:1637–1645.
2004.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Grossman WJ, Verbsky JW, Barchet W,
Colonna M, Atkinson JP and Ley TJ: Human T regulatory cells can use
the perforin pathway to cause autologous target cell death.
Immunity. 21:589–601. 2004.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Gumperz JE, Miyake S, Yamamura T and
Brenner MB: Functionally distinct subsets of CD1d-restricted
natural killer T cells revealed by CD1d tetramer staining. J Exp
Med. 195:625–636. 2002.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Nakata M, Kawasaki A, Azuma M, Tsuji K,
Matsuda H, Shinkai Y, Yagita H and Okumura K: Expression of
perforin and cytolytic potential of human peripheral blood
lymphocyte subpopulations. Int Immunol. 4:1049–1054.
1992.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Brennan AJ, Chia J, Trapani JA and
Voskoboinik I: Perforin deficiency and susceptibility to cancer.
Cell Death Differ. 17:607–615. 2010.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Voskoboinik I, Smyth MJ and Trapani JA:
Perforin-mediated target-cell death and immune homeostasis. Nat Rev
Immunol. 6:940–952. 2006.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Salcedo TW, Azzoni L, Wolf SF and Perussia
B: Modulation of perforin and granzyme messenger RNA expression in
human natural killer cells. J Immunol. 151:2511–2520.
1993.PubMed/NCBI
|
|
62
|
Zhang J, Scordi I, Smyth MJ and
Lichtenheld MG: Interleukin 2 receptor signaling regulates the
perforin gene through signal transducer and activator of
transcription (Stat)5 activation of two enhancers. J Exp Med.
190:1297–1308. 1999.PubMed/NCBI View Article : Google Scholar
|
|
63
|
García-Sanz JA and Podack ER: Regulation
of perforin gene expression in a T cell hybrid with inducible
cytolytic activity. Eur J Immunol. 23:1877–1883. 1993.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Uellner R, Zvelebil MJ, Hopkins J, Jones
J, MacDougall LK, Morgan BP, Podack E, Waterfield MD and Griffiths
GM: Perforin is activated by a proteolytic cleavage during
biosynthesis which reveals a phospholipid-binding C2 domain. EMBO
J. 16:7287–7296. 1997.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Pipkin ME and Lichtenheld MG: A reliable
method to display authentic DNase I hypersensitive sites at
long-ranges in single-copy genes from large genomes. Nucleic Acids
Res. 34(e34)2006.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Podack ER and Dennert G: Assembly of two
types of tubules with putative cytolytic function by cloned natural
killer cells. Nature. 302:442–445. 1983.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Podack ER, Young JD and Cohn ZA: Isolation
and biochemical and functional characterization of perforin 1 from
cytolytic T-cell granules. Proc Natl Acad Sci USA. 82:8629–8633.
1985.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Young JD, Cohn ZA and Podack ER: The ninth
component of complement and the pore-forming protein (perforin 1)
from cytotoxic T cells: Structural, immunological, and functional
similarities. Science. 233:184–190. 1986.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Young JD, Hengartner H, Podack ER and Cohn
ZA: Purification and characterization of a cytolytic pore-forming
protein from granules of cloned lymphocytes with natural killer
activity. Cell. 44:849–859. 1986.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Lowrey DM, Aebischer T, Olsen K,
Lichtenheld M, Rupp F, Hengartner H and Podack ER: Cloning,
analysis, and expression of murine perforin 1 cDNA, a component of
cytolytic T-cell granules with homology to complement component C9.
Proc Natl Acad Sci USA. 86:247–251. 1989.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Shinkai Y, Takio K and Okumura K: Homology
of perforin to the ninth component of complement (C9). Nature.
334:525–527. 1988.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Tschopp J, Masson D and Stanley KK:
Structural/functional similarity between proteins involved in
complement- and cytotoxic T-lymphocyte-mediated cytolysis. Nature.
322:831–834. 1986.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Lichtenheld MG, Olsen KJ, Lu P, Lowrey DM,
Hameed A, Hengartner H and Podack ER: Structure and function of
human perforin. Nature. 335:448–451. 1988.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Blumenthal R, Millard PJ, Henkart MP,
Reynolds CW and Henkart PA: Liposomes as targets for granule
cytolysin from cytotoxic large granular lymphocyte tumors. Proc
Natl Acad Sci USA. 81:5551–5555. 1984.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Henkart PA, Yue CC, Yang J and Rosenberg
SA: Cytolytic and biochemical properties of cytoplasmic granules of
murine lymphokine-activated killer cells. J Immunol. 137:2611–2617.
1986.PubMed/NCBI
|
|
76
|
Müllbacher A, Waring P, Tha Hla R, Tran T,
Chin S, Stehle T, Museteanu C and Simon MM: Granzymes are the
essential downstream effector molecules for the control of primary
virus infections by cytolytic leukocytes. Proc Natl Acad Sci USA.
96:13950–13955. 1999.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Nakajima H, Park HL and Henkart PA:
Synergistic roles of granzymes A and B in mediating target cell
death by rat basophilic leukemia mast cell tumors also expressing
cytolysin/perforin. J Exp Med. 181:1037–1046. 1995.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Shi L, Mai S, Israels S, Browne K, Trapani
JA and Greenberg AH: Granzyme B (GraB) autonomously crosses the
cell membrane and perforin initiates apoptosis and GraB nuclear
localization. J Exp Med. 185:855–866. 1997.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Spicer BA, Conroy PJ, Law RHP, Voskoboinik
I and Whisstock JC: Perforin-A key (shaped) weapon in the
immunological arsenal. Semin Cell Dev Biol. 72:117–123.
2017.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Voskoboinik I, Whisstock JC and Trapani
JA: Perforin and granzymes: Function, dysfunction and human
pathology. Nat Rev Immunol. 15:388–400. 2015.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Jenkins MR, Rudd-Schmidt JA, Lopez JA,
Ramsbottom KM, Mannering SI, Andrews DM, Voskoboinik I and Trapani
JA: Failed CTL/NK cell killing and cytokine hypersecretion are
directly linked through prolonged synapse time. J Exp Med.
212:307–317. 2015.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Voskoboinik I, Thia MC, Fletcher J,
Ciccone A, Browne K, Smyth MJ and Trapani JA: Calcium-dependent
plasma membrane binding and cell lygis by perforin are mediated
through its C2 domain: A critical role for aspartate residues 429,
435, 483, and 485 but not 491. J Biol Chem. 280:8426–8434.
2005.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Taylor MA, Ward B, Schatzle JD and Bennett
M: Perforin- and Fas-dependent mechanisms of natural killer
cell-mediated rejection of incompatible bone marrow cell grafts.
Eur J Immunol. 32:793–799. 2002.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Voskoboinik I and Trapani JA:
Perforinopathy: A spectrum of human immune disease caused by
defective perforin delivery or function. Front Immunol.
4(441)2013.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Molleran Lee S, Villanueva J, Sumegi J,
Zhang K, Kogawa K, Davis J and Filipovich AH: Characterisation of
diverse PRF1 mutations leading to decreased natural killer cell
activity in North American families with haemophagocytic
lymphohistiocytosis. J Med Genet. 41:137–144. 2004.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Rubin TS, Zhang K, Gifford C, Lane A, Choo
S, Bleesing JJ and Marsh RA: Perforin and CD107a testing is
superior to NK cell function testing for screening patients for
genetic HLH. Blood. 129:2993–2999. 2017.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Hernandez-Pigeon H, Jean C, Charruyer A,
Haure MJ, Titeux M, Tonasso L, Quillet-Mary A, Baudouin C,
Charveron M and Laurent G: Human keratinocytes acquire cellular
cytotoxicity under UV-B irradiation. Implication of granzyme B and
perforin. J Biol Chem. 281:13525–13532. 2006.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Hernandez-Pigeon H, Jean C, Charruyer A,
Haure MJ, Baudouin C, Charveron M, Quillet-Mary A and Laurent G:
UVA Induces Granzyme B in Human Keratinocytes through MIF
implication in extracellular matrix remodeling. J Biol Chem.
282:8157–8164. 2007.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Shrestha AC, Wijesundara DK, Masavuli MG,
Mekonnen ZA, Gowans EJ and Grubor-Bauk B: Cytolytic perforin as an
adjuvant to enhance the immunogenicity of DNA vaccines. Vaccines
(Basel). 7(38)2019.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Gargett T, Grubor-Bauk B, Garrod TJ, Yu W,
Miller D, Major L, Wesselingh S, Suhrbier A and Gowans EJ:
Induction of antigen-positive cell death by the expression of
Perforin, but not DTa, from a DNA vaccine enhances the immune
response. Immunol Cell Biol. 92:359–367. 2014.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Gummow J, Li Y, Yu W, Garrod T,
Wijesundara D, Brennan AJ, Mullick R, Voskoboinik I, Grubor-Bauk B
and Gowans EJ: A Multiantigenic DNA vaccine that induces broad
hepatitis C Virus-specific T-cell responses in mice. J Virol.
89:7991–8002. 2015.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Wijesundara DK, Yu W, Quah BJC, Eldi P,
Hayball JD, Diener KR, Voskoboinik I, Gowans EJ and Grubor-Bauk B:
Cytolytic DNA vaccine encoding lytic perforin augments the
maturation of- and antigen presentation by-dendritic cells in a
time-dependent manner. Sci Rep. 7(8530)2017.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Escher F, Kühl U, Lassner D, Stroux A,
Gross U, Westermann D, Pieske B, Poller W and Schultheiss HP: High
perforin-positive cardiac cell infiltration and male sex predict
adverse long-term mortality in patients with inflammatory
cardiomyopathy. J Am Heart Assoc. 6(e005352)2017.PubMed/NCBI View Article : Google Scholar
|
